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Summary
Objective: To investigate the role of adenosine analogs and electromagnetic ﬁeld (EMF) stimulation on prostaglandin E2 (PGE2) release and
cyclooxygenase-2 (COX-2) expression in bovine synovial ﬁbroblasts (SFs).
Methods: SFs isolated from synovia were cultured in monolayer. Saturation and binding experiments were performed by using typical aden-
osine agonists: N6-cyclohexyladenosine (CHA, A1), 2-[p-(2-carboxyethyl)-phenetyl-amino]-5
0-N-ethylcarboxamidoadenosine (CGS 21680,
A2A), 5
0-N-ethylcarboxamidoadenosine (NECA, non-selective), N6-(3-iodobenzyl)2-chloroadenosine-50-N-methyluronamide (Cl-IB-MECA,
A3). SFs were treated with TNF-a (10 ng/ml) and lipopolysaccharide (LPS) (1 mg/ml) to activate inﬂammatory response. Adenosine analogs
were added to control and TNF-a- or LPS-treated cultures both in the absence and in the presence of adenosine deaminase (ADA) which is
used to deplete endogenous adenosine. Parallel cultures were exposed to EMFs (75 Hz, 1.5 mT) during the period in culture (24 h). PGE2
release was measured by immunoassay. COX-2 expression was evaluated by RT-PCR.
Results: TNF-a and LPS stimulated PGE2 release. All adenosine agonists, except for Cl-IB-MECA, signiﬁcantly inhibited PGE2 production.
EMFs inhibited PGE2 production in the absence of adenosine agonists and increased the effects of CHA, CGS 21680 and NECA. In ADA,
the inhibition on PGE2 release induced by CHA, CGS and NECA was stronger than in the absence of ADA and the EMF-inhibitory effect
was lost. Changes in PGE2 levels were associated to modiﬁcation of COX-2 expression.
Conclusions: This study supports anti-inﬂammatory activities of A1 and A2A adenosine receptors and EMFs in bovine SFs. EMF activity
appears mediated by an EMF-induced up-regulation of A2A receptors. Biophysical and/or pharmacological modulation of adenosine pathways
may play an important role to control joint inﬂammation.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) and rheumatoid arthritis (RA) are the
most common degenerative diseases of the joints, charac-
terized by the progressive and permanent degradation of
the articular cartilage, synovial hypertrophy and change in
underlying bone. Although the pathophysiologic events of
OA and RA are quite different, inﬂammation and altered sy-
novial ﬁbroblasts (SFs) activities are observed in affected
joints1e6. In RA, SFs play a central role to the pathogenesis
of joint destruction by an increased proliferation and the
secretion of a wide range of pro-inﬂammatory mediators,
including cytokines, growth factors, and lipid mediators
of inﬂammation3,6. Pro-inﬂammatory mediators produced
by SFs are detrimental to articular cartilage also in
OA, although SFs play a less central role than in RA1,2.aThese authors contributed equally to this work.
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252Furthermore, SFs are involved in cartilage destruction via
the secretion of matrix degrading enzymes such as matrix
metalloproteinases (MMPs) and aggrecanases7e9. Prosta-
glandins, in particular prostaglandin E2 (PGE2), are impor-
tant lipid inﬂammatory mediators produced by SFs and
their levels are increased in the synovial ﬂuid and synovial
membrane of patients with joint diseases10e13. PGE2 is
synthesized from arachidonic acid via the actions of cyclo-
oxygenase (COX) enzymes, either constitutively or in
response to cell trauma, stimuli, or signaling molecules
such as interleukin-1b (IL-1b) or tumor necrosis factor alpha
(TNF-a) and it accounts for many of the pro-inﬂammatory
actions induced by these peptides14e16. PGE2 contributes
to vasodilatation, vascular permeability, pain, cytokine and
proteinase production in inﬂamed tissues17e19. Accordingly,
the use of non-steroidal anti-inﬂammatory drugs (NSAIDs)
and/or selective COX-2 inhibitors which control inﬂamma-
tion and inhibit PGE2 production represent the standard
recommended treatment of OA and RA20e22. Alternative
potential therapeutical approaches to control inﬂammation
and manage joint diseases are suggested by studies which
investigated the role of adenosine23e27 and biophysical
stimulation by electromagnetic ﬁelds (EMFs) in cartilage
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G-protein-coupled receptors (A1, A2A, A2B, A3) acts as a po-
tent endogenous inhibitor of inﬂammatory processes in sev-
eral tissues29e32. In SFs and chondrocytes adenosine has
been involved in the production of MMPs and inﬂammatory
mediators23e25,33,34. In vivo adenosine analogs inhibit joint
destruction when used in the treatment of adjuvant induced
arthritis and septic arthrosis25,26,35. EMFs display several
effects on different tissues, including bone and cartilage.
In vitro, EMFs increase cytokine and growth factors produc-
tion36 and stimulate osteoblasts and chondrocytes prolifer-
ation37,38. In cartilage explants, EMF exposure increases
proteoglycan synthesis, prevents the catabolic effect of
the pro-inﬂammatory cytokine IL-1 and acts in synergy
with insulin-like growth factor-I39e41. Further, in vivo EMFs
preserve the morphology of articular cartilage and retard
the development of osteoarthritic lesions in guinea pigs; in
humans they appear useful for the treatment of OA and to
control joint inﬂammation after arthroscopic surgery42e45.
Recent studies, showing that EMFs evoke a speciﬁc up-
regulation of the A2A and A3 adenosine receptors, suggest
that EMFs may have anti-inﬂammatory activities mediated
by the up-regulation of adenosine receptors46e48.
On the bases of the above observations and of the role of
SFs to elicit and to maintain joint inﬂammation, we investi-
gated if adenosine receptor agonists and EMF biophysical
stimulation, alone or combined, might limit PGE2 release
in SFs treated with known inﬂammatory stimuli: TNF-
a and the bacterial lipopolysaccharide (LPS)8,11,12,49.
COX-2 expression was evaluated by RT-PCR as it appears
to be the primary enzyme controlling PGE2 synthesis in
response to inﬂammatory stimuli10,16. Further, adenosine
analogs were used to characterize the presence of adeno-
sine receptors and their afﬁnity in bovine SFs, in the
absence and in the presence of EMFs.Materials and methodsSF CULTURESSFs were obtained by culture of the bovine synovial ﬂuid, aspirated from
the metacarpophalangeal joints of 14e18-month-old animals, as previously
described46,50. SFs at the third-fourth passage were used in the experiments.
Cells were characterized by immunoﬂuorescence staining with vimentin,
a marker for ﬁbroblasts51. To conﬁrm that SF cultures were not contaminated
by macrophages, CD14 expression was evaluated by RT-PCR.IMMUNOFLUORESCENCE STAININGSFs were ﬁxed with cold methanol, washed with phosphate-buffered sa-
line (PBS) and incubated with the primary monoclonal antibody (mAb) for
the human vimentin (SigmaeAldrich, Italy) at 1:200 dilution for 1 h at 37C.
Washed slides were then incubated with a secondary ﬂuorescein isothiocya-
nate-conjugated goat anti-mouse antibody for 1 h at 37C. Nuclei were
stained with the DNA dye, 40,6-diamidino-2-phenylindole (DAPI) (0.1 mg/ml
in PBS ethylene glycol tetraacetic acid (EGTA)) for 10 min. Fluorescence
was visualized using the Nikon Eclipse TE 2000-E microscope (Nikon Instru-
ments, Italy) equipped with a digital camera (DXM 1200F).REVERSE TRANSCRIPTION POLYMERASE CHAIN
REACTION (RT-PCR)CD14 and COX-2 expression in SFs cultures was assayed by RT-PCR.
Total RNA extraction was performed by a commercial kit (RNeasy Kit,
Qiagen, Deutschland). RNA conversion to cDNA was performed by the
kit SuperscriptTM First-Strand Synthesis System (Invitrogen, USA).
Oligonucleotide primers for CD14 were dp50-CTGGAAGCCGGCG-30;
rp50AGCTGAGCAGGAACCTGTGC-30 and oligonucleotides for glyceraldehyde
3-phosphate dehydrogenase (GAPDH) were dp50-TGGCAT CGTGGAGG-
GACTTAT-30; rp50-GACTTCAACAGCGACACTCAC-30. Sequences were
selected to amplify both human and bovine genome. Oligonucleotides forCOX-2 were dp50-TCCAGATCACATTTGATTGACA-30; rp50-
TCTTTGACTGTGGGAGGATACA-3052. Oligonucleotides sequences were
from separate exons to exclude genomic DNA contaminations. Two
microliters of cDNA were ampliﬁed by the speciﬁc oligonucleotide sets and
PCR reactions were performed as previously described46. Cycling parame-
ters were as follows: 1 min at 94C; 1 min at the speciﬁc annealing temper-
ature (55C for CD14, 61C for GAPDH, 60C for COX-2); and 1 min at
72C. PCR product sizes were 403 bp for CD14, 370 bp for GAPDH and
450 bp for COX-2. mRNA from human macrophages was used as a positive
control for CD14 expression. PCR products were analyzed on 1.5% agarose
gel, stained with ethidium bromide and visualized under UV.CHARACTERISTICS OF EMFsThe EMF generator system used in binding and PGE2 functional assays
was the same used in previous studies (I-ONE, Igea, Carpi, Italy)39e41,46e48.
The magnetic ﬁeld was generated by a pair of circular coils of copper wire
placed opposite to each other. The coils were powered by the generator sys-
tem, which produced the input voltage of pulse. The pulse duration of the sig-
nal was 1.3 ms and the repetition rate 75 Hz, yielding a duty cycle of 1/10.
The intensity peak of the magnetic ﬁeld was 1.5 mT and the induced electric
ﬁeld, as detected with a standard coil probe (50 turns, 0.5 cm internal diam-
eter of the coil probe, 0.2 copper diameter), was 0.07 mV/cm.SATURATION AND COMPETITION BINDING EXPERIMENTS TO
ADENOSINE RECEPTORSSFs, used for cellular membrane preparations, were washed with PBS and
scraped off T75 ﬂasks in ice-cold hypotonic buffer (5 mM Tris HCl, 2 mM ethyl-
enediaminetetraacetic acid (EDTA), pH 7.4). The cell suspension was homog-
enized by aPolytron, centrifuged for 30 min at 100,000g and used in saturation
and competition binding experiments46e48. Saturation experiments to A1 re-
ceptors were performed using [3H]-N6-cyclohexyladenosine ([3H]-CHA,
34.4 Ci/mmol; NEN e Perkin Elmer, USA) as radioligand for an incubation
time of 90 min53. Non-speciﬁc binding was determined in the presence of
CHA 1 mM. Saturation experiments to A2A receptors were performed using
[3H]-2-[p-(2-carboxyethyl)-phenetyl-amino]-50-N-ethylcarboxamidoadenosine
([3H]-CGS 21680, 39.6 Ci/mmol; NEN e Perkin Elmer, USA) as radioligand
with an incubation time of 120 min54. Non-speciﬁc binding was determined
with CGS 21680 1 mM. Saturation experiments to A2B receptors were per-
formed using [3H]-N-benzo [1,3[dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-
2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl-oxy]-acetamide
([3H]-MRE 2029F20, 123 Ci/mmol; Amersham Laboratories, UK) as radioli-
gand for 60 min55. Non-speciﬁc binding was determined with MRE 2029F20
1 mM. Saturation experiments to A3 receptors were performed using [
125I]-4-
aminobenzyl-50-N-methylcarboxamidoadenosine ([125I]-AB-MECA, 2000 Ci/
mmol; Amersham Laboratories, UK) as radioligand, for 60 min56. Non-speciﬁc
bindingwas determinedwithAB-MECA1 mM. In competition experiments, car-
riedout to determineA1,A2A,A2BandA3afﬁnity values, 1 nM radioligandswere
used on SFmembranes (100 mg protein per assay) and 6e8 different concen-
trations of the examined agonists. At the end of incubation time, in binding ex-
periments performed in unexposed and EMF-exposed SFmembranes, bound
and free radioactivities were separated by ﬁltering the assay mixture through
Whatman GF/B ﬁlters (Brandel Harvester) and radioactivity was counted
(Scintillation Counter Packard Tri Carb 2500TR).SF TREATMENTS WITH ADENOSINE AGONISTS
AND EMF EXPOSUREFor the analysis of PGE2 release, SFs at third-fourth passage were plated
at 10,000/cm2 in complete medium (Dulbecco’s modiﬁed Eagle’s/Ham’s F12
(1:1) medium (DMEM/F12) containing 10% fetal bovine serum (FBS) and an-
tibiotics) in multiwells (Nunc, Denmark, 1.6 cm the diameter of each well) and
used after 5 days plating. In preliminary experiments increasing doses of the
recombinant human TNF-a (Preprotech, USA) and the bacterial LPS (Sigma,
USA) selected in the range of those used in previous studies, were
tested11,12,49. In the following experiments TNF-a and LPS were used, re-
spectively, at 10 ng/ml and 1 mg/ml, which elicited maximal PGE2 increase
in preliminary experiments. Control cells were incubated in complete medium
alone. In a ﬁrst series of experiments adenosine analogs were added to both
control and TNF-a- or LPS-treated cultures in the presence of endogenous
adenosine. The adenosine agonists CHA (A1), CGS 21680 (A2A), 5
0-N-ethyl-
carboxamidoadenosine (NECA) (non-selective), and N6-(3-iodobenzyl)
2-chloroadenosine-50-N-methyluronamide (Cl-IB-MECA) (A3) were used at
1 mM (Sigma, USA). In a second series of experiments, treatments with aden-
osine agonists in the presence of TNF-a or LPS were performed in complete
medium containing 2 IU/ml adenosine deaminase (ADA, FlukaeSigmae
Aldrich, Switzerland) to deplete endogenously released adenosine. Different
ADA concentrations (0.5e4 IU/ml) were analyzed on PGE2 release and cell
viability to evaluate the effect of endogenous adenosine.
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described above, were exposed to EMFs during the whole treatment period.
In some experiments, 1 mM forskolin (Sigma, USA), a direct activator of ad-
enylate cyclase, was added to both control and TNF-a-treated cultures in the
absence and the presence of EMFs57. At each condition tested, after 24 h treat-
ment, medium was removed from the well, stored at 80C for subsequent
determination of PGE2 and the monolayer protein content was evaluated
58.PGE2 ASSAYThe concentration of PGE2 was measured using a commercially available
competitive enzyme immunoassay according to the manufacturer’s instruc-
tions (PGE2 Assay, R&D Systems, Inc., Minneapolis, USA). Samples and
standards were assayed in duplicate. PGE2 production was normalized to
the total protein content and expressed as pg PGE2/mg protein.MTT ASSAYEffects of ADA on cell proliferation and viability of SFs were evaluated
by the MTT assay59,60. Brieﬂy, 100 ml of MTT solution (5 mg/ml in PBS)
(SigmaeAldrich, UK) were added to each well and incubated at 37C for
3 h. The medium was then discarded and 500 ml of isopropanol/HCl
0.04 N were added to each well for the formazan solubilization. The solu-
tion absorbance was measured at 540 nm (Cary-50, UVeVisible Spectro-
photometer, Varian).STATISTICAL ANALYSISData were obtained from at least ﬁve independent experiments. Each
experiment was performed in triplicate. All values are expressed as
mean S.E. of independent experiments. Analysis of data was done with
Student’s t test. Differences were considered signiﬁcant at a value of
P< 0.05.ResultsPHENOTYPE CHARACTERIZATION OF SFsSFs used in our experiments are shown in Fig. 1. Cells
showed a ﬁbroblast-like morphology and the expression of
vimentin, the main intermediate ﬁlament protein in mesen-
chymal cells and SFs51. Results obtained by RT-PCR
showed the absence of CD14 expression, indicating the
absence of contaminating macrophages8.EVALUATION OF ADENOSINE RECEPTOR AFFINITY
AND DENSITY BY SATURATION AND COMPETITION
BINDING EXPERIMENTSFig. 1. Bovine SFs in culture. (A) Phase contrast. (B) Vimentin ex-
pression by immunoﬂuorescence. Nuclei were counterstained in
blue with DAPI. (C) CD14 mRNA expression in macrophages
(MC) and in bovine SFs (C, upper panel). M is 100 bp DNA ladder
marker (Biolabs). One microgram of total RNA was loaded for lane
and stained with ethidium bromide to conﬁrm equal RNA quantity
used for RT-PCR (C, lower panel).Table I reports the afﬁnity (KD, nM) and density (Bmax,
fmol/mg protein) of A1, A2A, A2B and A3 receptors in unex-
posed or EMF-exposed SF membranes. The afﬁnity values
of adenosine receptor subtypes and the Bmax values of A1
and A2B receptors were strictly similar in both EMF-treated
and untreated cells. In contrast, after EMF treatment, the
Bmax values of A2A and A3 receptors were increased of
2.33- and 2.15-fold in comparison to control, respectively,
(*P< 0.01 vs untreated cells, Table I). Table II reports the
afﬁnity values (Ki, nM) of CHA, NECA, CGS 21680 and
Cl-IB-MECA in untreated and EMF-treated bovine SFs.
The major afﬁnity of CHA (Ki¼ 3.5 nM) was reported in
[3H]-CHA binding suggesting a high afﬁnity vs A1 receptors.
NECA and CGS 21680 showed similar afﬁnity for A2A
receptors even if NECA had a good afﬁnity also for the other
subtypes. Cl-IB-MECA showed a high afﬁnity vs A3 receptors
with a Ki value of 2.3 nM. In summary results of Tables I and II
showed that EMFs induced an increase in A2A and A3 recep-
tor density (Bmax values) without modifying the receptor capa-
bility to bind the speciﬁc ligands (KD, Ki values or afﬁnity).
Saturation and competition binding experiments allowed to
select, on the basis of the Ki values, the adenosine agonist
concentrations to be used in subsequent experiments.TNF-a AND LPS INDUCE A DOSE RESPONSE INCREASE ON
PGE2 RELEASE IN SFsIn preliminary experiments we investigated the effects of
increasing doses of TNF-a and LPS, which are known to
stimulate PGE2 production in human SFs, on PGE2 release
Table I
Affinity and density of adenosine receptors in bovine SFs
SFs [3H]-CHA binding [3H]-CGS 21680 binding [3H]-MRE 2029F20 binding [125I]-AB-MECA binding
Untreated KD¼ 1.82 0.16 nM KD¼ 4.6 0.5 nM KD¼ 1.32 0.12 nM KD¼ 1.65 0.15 nM
Bmax¼ 24 3 fmol/mg
protein
Bmax¼ 62 6 fmol/mg
protein
Bmax¼ 78 8 fmol/mg
protein
Bmax¼ 65 6 fmol/mg
protein
EMF treated KD¼ 1.78 0.17 nM KD¼ 4.9 0.4 nM KD¼ 1.26 0.11 nM KD¼ 1.54 0.14 nM
Bmax¼ 22 3 fmol/mg
protein
Bmax¼ 145 12 fmol/mg
protein*
Bmax¼ 74 7 fmol/mg
protein
Bmax¼ 140 13 fmol/mg protein*
Data are expressed as the meanS.E. (n¼ 4). *P< 0.01 vs untreated cells.
255Osteoarthritis and Cartilage Vol. 17, No. 2in bovine SF cultures (Fig. 2)11,49. PGE2 production by con-
trol SFs was at very low levels. TNF-a and LPS signiﬁcantly
increased PGE2 production in a dose-dependent manner.
The most efﬁcient doses were 10 ng/ml for TNF-a and
1 mg/ml for LPS yielding a maximal 7.9- and 9.8-fold in-
crease, respectively. On these results, these TNF-a and
LPS doses were used to stimulate PGE2 production in sub-
sequent experiments.ADENOSINE AGONISTS AND EMF EXPOSURE INHIBIT PGE2
RELEASE IN TNF-a- OR LPS-TREATED SFs IN THE PRESENCE
OF ENDOGENOUS ADENOSINEThe effects of adenosine agonists and EMFs on PGE2 re-
lease in TNF-a or LPS unstimulated and stimulated SFs, in
the presence of endogenous adenosine, are shown in
Fig. 3. Treatment of cells with the A1 agonist CHA, the
A2A agonist CGS 21680, the non-selective agonist NECA
and the A3 agonist Cl-IB-MECA did not modify basal
PGE2 production in the absence of TNF-a or LPS. Similarly,
EMFs did not modify basal PGE2 production, both in the ab-
sence and in the presence of the agonists [Fig. 3(A)].
In TNF-a stimulated SFs, all agonists, except for Cl-IB-
MECA, signiﬁcantly inhibited PGE2 production. PGE2 inhibi-
tion ranged from 38.6% in the presence of CHA to 54.9% in
the presence of NECA [Fig. 3(B)]. Similar data were ob-
tained in LPS stimulated SFs [Fig. 3(C)]. When TNF-a or
LPS stimulated SFs were exposed to EMFs, PGE2 produc-
tion was signiﬁcantly inhibited by EMFs, respectively, of
62.7% in the presence of TNF-a and 48.5% in the presence
of LPS. Similar inhibitions were induced by EMFs in TNF-a or
LPS stimulated SFs cultured in the presence of Cl-IB-
MECA. Interestingly, in the presence of CHA, CGS 21680Table II
Affinity (Ki) of typical adenosine agonists to bovine SFs
[3H]-CHA
binding
Ki (nM)
[3H]-CGS
21680
binding
Ki (nM)
[3H]-MRE
2029F20
binding
Ki (nM)
[125I]-AB-
MECA
binding
Ki (nM)
Untreated
CHA 3.5 0.4 812 75 >1000 83 7
NECA 22 2 8.4 0.8 156 17 36 4
CGS 21680 740 70 7.2 0.7 >1000 985 90
Cl-IB-MECA 185 22 643 60 >1000 2.3 0.2
EMF treated
CHA 3.1 0.3 805 72 >1000 86 8
NECA 20 2 8.1 0.8 163 18 35 3
CGS 21680 725 65 7.5 0.7 >1000 976 86
Cl-IB-MECA 178 18 637 58 >1000 2.7 0.3
Data are expressed as the meanS.E. (n¼ 4).and NECA, EMFs signiﬁcantly increased the inhibitory ac-
tivity of the agonists on TNF-a- or LPS-induced PGE2 pro-
duction [Fig. 3(B,C)]. The combined effects of adenosine
agonists and EMFs reduced PGE2 levels to those of unsti-
mulated control cells.
Adenosine agonists were used at 1 mM, the concentration
that assured a complete saturation of adenosine receptors
as suggested from the afﬁnity values (Ki, nM) of Table II.DEPLETION OF ENDOGENOUS ADENOSINE WITH
ADA INCREASES BASAL PGE2 RELEASE IN SFsSFs were exposed to increasing doses of ADA
(0.5e2 IU/ml) to determine the effects of depleting endoge-
nous adenosine. PGE2 release slightly but signiﬁcantly in-
creased in a dose-dependent manner with maximal effect
at 2 IU/ml [Fig. 4(A)]. In parallel experiments, MTT assay
was performed to verify that in our experimental conditions
ADA did not modify SF proliferation or viability24. At all the
doses, ADA had no effect on cell proliferation and viability
[Fig. 4(B)].DEPLETION OF ENDOGENOUS ADENOSINE WITH ADA
POTENTIATES ADENOSINE AGONISTS’ EFFECTS BUT
LIMITS EMF-INHIBITORY EFFECTS ON PGE2 RELEASE IN
TNF-a- OR LPS-TREATED SFsAs 2 IU/ml ADA induced the maximal increase in PGE2
production, this dose was used to deplete endogenous
adenosine (Fig. 5). Both TNF-a and LPS signiﬁcantly stim-
ulated PGE2 synthesis similarly to what observed in the ab-
sence of ADA. Also, Cl-IB-MECA did not modify PGE2
levels in TNF-a or LPS stimulated cells. In TNF-a or LPS
stimulated SFs, CHA, CGS 21680 and NECA induced
a stronger inhibition on PGE2 production than in the ab-
sence of ADA. In fact, CHA, CGS 21680 and NECA re-
duced PGE2 levels to those of unstimulated control cells,
and in these experimental conditions EMFs did not further
decrease PGE2 levels. Finally, when TNF-a or LPS stimu-
lated SFs cultured in the presence of ADA were exposed
to EMFs alone, the effect on PGE2 release reduction was
signiﬁcantly lower than that observed in SFs cultured with-
out ADA. This lower activity of EMFs in ADA was also
observed in the presence of Cl-IB-MECA.FORSKOLIN STIMULATES PGE2 RELEASE IN ACTIVATED SFsAs shown in Figs. 3 and 5, CHA (A1 agonist) and CGS
21680 (A2A agonist), which inhibit and stimulate adenylate
cyclase, respectively, decreased PGE2 release in TNF-
a or LPS stimulated SFs. To clarify the potential involve-
ment of adenylate cyclase activity in the modulation of
PGE-2 release in stimulated synovial fibroblasts
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256 M. De Mattei et al.: Adenosine receptors and EMF on PGE2 releasePGE2 production, we investigated the effects of forskolin,
a potent stimulator of adenylate cyclase, on PGE2 release
57.
Forskolin did not modify basal PGE2 levels in the absence
(control¼ 11.8; forskolin¼ 14.9, pg/mg protein) and the pres-
ence of EMFs (control¼ 11.2; forskolin¼ 7.2, pg/mg protein).
However, in SFs activated by the inﬂammatory stimuli, for-
skolin induced a further 24.3% increase in PGE2 release
(activated SFs¼ 123.1; activated SFsþ forskolin¼ 159.3,
pg/mg protein; P< 0.05). The effect of EMFs on PGE2 re-
lease was not signiﬁcantly modiﬁed by the presence of for-
skolin in culture (activated SFsþEMF¼ 55.4; activated
SFsþ forskolinþ EMF¼ 88.2, pg/mg protein).CHANGES IN COX-2 EXPRESSION ARE ASSOCIATED TO THE
CHANGES IN PGE2 RELEASE INDUCED BY ADENOSINE
AGONISTS AND EMF EXPOSURE IN TNF-a- OR
LPS-TREATED SFsSince PGE2 levels were regulated by adenosine agonists
and EMFs, we investigated whether changes in PGE2 re-
lease were associated to a regulation of COX-2 transcripts.
COX-2 expression, evaluated by RT-PCR, at 24 h treatment,
is shown in Fig. 6. As reported in literature, in our experi-
ments the stimulation of PGE2 synthesis induced by TNF-
a and LPS was associated to an increase of COX-2 ex-
pression with respect to control cells11,16,49. All adenosine
agonists, except for Cl-IB-MECA, inhibited COX-2 expres-
sion in TNF-a or LPS stimulated cells. EMFs inhibited
COX-2 expression in both control and TNF-a or LPS stimu-
lated SFs, also in the presence of Cl-IB-MECA. The inhibition
induced by CHA, NECA and CGS on COX-2 expression in
TNF-a or LPS stimulated cells was enhanced by EMF expo-
sure, mirroring the changes observed in PGE2 levels.
Discussion
In this study we investigated how adenosine receptor ag-
onists and EMF exposure, alone or combined, might modify
PGE2 release in SFs treated with pro-inﬂammatory stimuli.Saturation binding experiments conﬁrmed the presence
of A1, A2A, A2B and A3 receptors in SFs and that EMFs in-
duced an up-regulation of A2A and A3 receptors, without any
change in the afﬁnity46e48. The afﬁnity values calculated for
each adenosine agonist, allowed to select the agonist work-
ing concentration to use in functional experiments.
In agreement with previous studies, TNF-a and LPS in-
duced an approximately 8e10-fold increase in PGE2 levels
in SFs11,12,49. In a ﬁrst series of experiments we analyzed
the effects of adenosine agonists in the presence of endog-
enous adenosine. All the agonists had no effect on basal
PGE2 release, however, CHA, NECA and CGS 21680
caused a signiﬁcant inhibition on PGE2 increase induced
by TNF-a and LPS. These data indicate for the ﬁrst time
the involvement of A1 and A2 receptors in the negative mod-
ulation of PGE2 synthesis in SFs. Cl-IB-MECA did not mod-
ify PGE2 production suggesting that the activation of the A3
receptor is not involved in the modulation of PGE2 synthe-
sis. As endogenous adenosine potentially could mask the
selective involvement of a speciﬁc adenosine receptor, we
investigated the agonist effects also in the presence of
ADA, an enzyme capable to deplete adenosine levels by
its ability to convert adenosine to inosine24. The presence
of ADA increased basal PGE2 levels, conﬁrming the
involvement of adenosine in modulating PGE2 production,
a ﬁnding consistent with the ﬁrst series of experiments
and with previous studies in cartilage cells24,27. Further, in
cells treated with TNF-a and LPS, CHA, NECA and CGS
21680 induced a stronger PGE2 inhibition than in the
absence of ADA; this can be explained by the increased
potency of adenosine agonists in comparison to adenosine.
Collectively, our results show that A1 and A2A adenosine
receptors are involved in the inhibition of PGE2 production
in SFs. The similar effects on PGE2 release obtained by
using NECA (non-selective agonist) and CGS 21680 (A2A
agonist) suggest that A2B receptors are not involved in
this functional response. In addition, the lack of an effect
of Cl-IB-MECA excludes a role for the A3 receptors in mod-
ulating PGE2 production.
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258 M. De Mattei et al.: Adenosine receptors and EMF on PGE2 releaseThe canonical transduction pathway coupled to A1 and
A2A receptors include, respectively, the inhibition and the
stimulation of adenylate cyclase with consequent reduction
and increase in cAMP levels. As both A1 and A2A agonists
inhibited PGE2 release to a similar degree, this suggested
that cAMP changes were not involved in the PGE2 inhibi-
tion. Therefore, as a positive control for the adenylate cy-
clase activation, we investigated the effects of forskolin,
a direct activator of this enzyme, on PGE2 release
46,57. For-
skolin increased PGE2 release in stimulated SFs conﬁrming
that the PGE2 release inhibition observed in our experi-
ments was not linked to cAMP production; these ﬁndings
are consistent with the results described by Kojima
et al.61 in human SFs. Other signal transduction pathways,
activated by adenosine receptors, might be involved in the
negative regulation of PGE2 production
62,63.
This and previous studies have shown that EMFs induce
the up-regulation of adenosine receptors; here we evalu-
ated the effects of EMF exposure and its possibleinteraction with adenosine receptor activity on PGE2 pro-
duction. Similarly to what observed for the adenosine ago-
nists, EMFs did not modify basal PGE2 production.
However, in the presence of endogenous adenosine,
EMFs strongly inhibited TNF-a- or LPS-induced PGE2 re-
lease, respectively of 63 and 49%. Further, EMFs strongly
enhanced the inhibitory activity of adenosine agonists on
PGE2 release. Since synergistic or additive actions among
adenosine agonists and EMFs have not been deﬁnitely
proven, our results cannot permit to drive deﬁnite conclu-
sions concerning the EMF action mechanism. However,
some lines of evidence seem to indicate that the ability of
EMFs to inhibit PGE2 production might be mediated by
the adenosine pathway. In fact, the increased number of
A2A receptors observed in SFs exposed to EMFs (Bmax, Ta-
ble I) was associated to the enhanced inhibition of PGE2 re-
lease induced by adenosine agonists in the presence of
EMFs. Further, in conditions of depleted endogenous aden-
osine, the ability of EMF exposure to inhibit PGE2
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259Osteoarthritis and Cartilage Vol. 17, No. 2production in TNF-a- and LPS-treated cells was almost lost,
suggesting that adenosine is necessary to mediate EMF ef-
fects. Indeed, our ﬁndings show for the ﬁrst time that EMFs
can inhibit inﬂammatory activities in SFs and act in concert
with adenosine analogs by enhancing this cellular
response.
Finally, our results show that the ability of adenosine ag-
onists and EMFs to inhibit PGE2 release is mediated by
a down-regulation of TNF-a- and LPS-induced COX-2
mRNA expression. Worth of note, a similar effect is also
induced in human SFs by known anti-inﬂammatory
drugs12.
The pharmacologic PGE2 blockade by aspirin, NSAIDs
and COX-2 inhibitors has been a useful anti-inﬂammatory
strategy for more than a century, however, it is known that
the appearance of side-effects may limit the chronic use
of these drugs. The ﬁndings of the present study open
new perspectives to the control of inﬂammation associated
to joint diseases. It is to note that both adenosine and EMFs
modulate chondrocyte activities too. In cartilage cells, aden-
osine and the A2A receptor have been involved in theinhibition of inﬂammatory and matrix degradative
events23,24 and EMFs promote anabolic activities and pre-
vent cartilage degradation39e41. Thus, previous observa-
tions and the results of this study suggest that adenosine
analogs in combination with EMFs, may reduce inﬂamma-
tion and cartilage degradation in articular joints, by targeting
both SFs and chondrocytes. Indeed, in vivo, the separate
ability of adenosine analogs and EMFs to limit joint destruc-
tion has been previously proven in animal
models25,26,28,42,43.
In conclusion, our results add new relevant data in the
analysis of adenosine anti-inﬂammatory activities by
showing the involvement of A1 and A2A adenosine recep-
tors in the inhibition of SFs responses to inﬂammatory
stimuli. Further, this study shows that EMFs can regulate
inﬂammatory parameters in SFs through the modulation
of adenosine mediated anti-inﬂammatory pathway. From
a clinical point of view, the pharmacological and/or bio-
physical modulation of adenosine pathways might have
relevant therapeutic potential for the treatment of joint in-
ﬂammatory diseases.
Fig. 6. Effects of adenosine receptor agonists and EMFs on control and TNF-a (upper panel) or LPS (lower panel) induced COX-2 expression
evaluated by RT-PCR, at 24 h treatment. GAPDH expression was used as control gene. M is DNA molecular weight marker VIII (Roche
Diagnostics GmbH, Germany).
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